IMCC
IM Cannabis Corp.
There isn't enough reported data to score IMCC yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IMCC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Weak |
IMCC's revenue, profitability, cash flow and balance sheet are all currently weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
IMCC PE Valuation
IMCC has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
IMCC Forward outlook
There aren't enough analyst estimates for IMCC to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
IMCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2020 | -$629.57 | -$607.83 |
IMCC lost $629.57 per share over the past year, a bigger loss than the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over IMCC in the latest year-over-year earnings comparison.
IMCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.3M | -40% |
| Q1 2026 | $6.1M | -31% |
| Q4 2025 | $7.9M | -16% |
| Q3 2025 | $9.7M | -0.2% |
| Q2 2025 | $8.9M | -14% |
| Q1 2025 | $8.8M | +3.6% |
| Q4 2024 | $9.4M | +25% |
| Q3 2024 | $9.8M | +12% |
IMCC's revenue has slid since its 2024 peak: $5M last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -28% | -25 points |
| Q1 2026 | -19% | -21 points |
| Q4 2025 | -25% | +123 points |
| Q3 2025 | -30% | -37 points |
| Q2 2025 | -2.8% | -22 points |
| Q1 2025 | 1.3% | +48 points |
| Q4 2024 | -148% | -99 points |
| Q3 2024 | 6.9% | -11 points |
IMCC's operating margin was −28% last quarter, down 25 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over IMCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over IMCC on profitability, with a higher operating margin.
IMCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$927.5K | -$610.6K |
| Q1 2026 | -$134.3K | -104% |
| Q4 2025 | $1.9M | +$4.8M |
| Q3 2025 | -$2.5M | -231% |
| Q2 2025 | -$317K | -234% |
| Q1 2025 | $3.1M | +$3.6M |
| Q4 2024 | -$3M | -$2.8M |
| Q3 2024 | $1.9M | -50% |
IMCC has burned cash in most quarters: −$2M over the past year, against $2M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over IMCC on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +35.5K shares |
| 1 year | +166% | +123K shares |
| 3 years | +680% | +172K shares |
IMCC has 197,633 diluted shares, up 166% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over IMCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
IMCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | 14.0x | High |
| Q4 2023 | 26.3x | High |
IMCC's net debt is about 14 years of its operating earnings (EBITDA).
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
IMCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 0.6 | Oversold |
IMCC's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
IMCC PE vs Healthcare Sector
IMCC has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IMCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.34 | 59% below |
| 20 week MA | $2.68 | 79% below |
| 50 week MA | $15.3 | 96% below |
| 100 week MA | $40.2 | 99% below |
| 200 week MA | $75.3 | 99% below |
IMCC is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over IMCC on trend strength, trading above more of its moving averages.
IMCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3,556.8 | $15,120.0 | +325% |
| 2021 | $15,120.0 | $6,516.0 | -57% |
| 2022 | $6,516.0 | $189.0 | -97% |
| 2023 | $189.0 | $64.2 | -66% |
| 2024 | $64.2 | $73.2 | +14% |
| 2025 | $73.2 | $42.9 | -41% |
| 2026 YTD | $42.9 | $0.55 | -99% |
IMCC's yearly returns have swung widely, from +325% in 2020 to −97% in 2022. It's down 99% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over IMCC on returns for 2026, with the stronger performance.